Enforcement
We enforce federal competition and consumer protection laws that prevent anticompetitive, deceptive, and unfair business practices.
,
Search or browse
the Legal Library
Find legal resources and guidance to understand your business responsibilities and comply with the law.
,
Take action
- Report an antitrust violation
- File adjudicative documents
- Find banned debt collectors
- View competition guidance
,
Competition Matters,
John Newman & Amy Ritchie, Bureau of Competition,
,
Policy
We work to advance government policies that protect consumers and promote competition.
,
Search or browse
the Legal Library
Find legal resources and guidance to understand your business responsibilities and comply with the law.
,
Take action
,
Technology Blog,
Nick Jones,
,
Advice and Guidance
Learn more about your rights as a consumer and how to spot and avoid scams. Find the resources you need to understand how consumer protection law impacts your business.
,
Take action
- Report fraud
- Report identity theft
- Register for Do Not Call
- Sign up for consumer alerts
- Get Business Blog updates
- Get your free credit report
- Find refund cases
- Order bulk publications
,
Consumer Advice
- Shopping and Donating
- Credit, Loans, and Debt
- Jobs and Making Money
- Unwanted Calls, Emails, and Texts
- Identity Theft and Online Security
- Scams
,
Business Guidance
- Advertising and Marketing
- Credit and Finance
- Privacy and Security
- By Industry
- For Small Businesses
- Browse Business Guidance Resources
- Business Blog
,
Servicemembers:
Your tool for financial readiness
,
Get consumer protection basics, plain and simple
,
Learn how the FTC protects free enterprise and consumers
,
Looking for competition guidance?
,
News and Events
,
,
Follow us on social media
,
About the FTC
Our mission is protecting consumers and competition by preventing anticompetitive, deceptive, and unfair business practices through law enforcement, advocacy, and education without unduly burdening legitimate business activity.
,
Looking for legal documents or records? Search the Legal Library instead.
,
Looking for legal documents or records? Search the Legal Library instead.
,
For Release,
,
The Federal Trade Commission filed an amicus brief to address the anticompetitive harm that stems from improperly listed patents in the Food and Drug Administration’s (FDA) publication of “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the “Orange Book.”
The Commission’s filing relates to an antitrust case brought by drug manufacturer Mylan Pharmaceuticals Inc. and several other affiliated entities alleging that Sanofi-Aventis U.S. LLC and other affiliated entities have engaged in anticompetitive conduct to monopolize the market for injectable insulin glargine, a drug used to treat diabetes. Mylan alleges Sanofi monopolized the injectable insulin glargine market in part by abusing the FDA’s Orange Book regulatory process. Specifically, Mylan alleges Sanofi delayed and blocked Mylan’s generic drug called Semglee from competing with Sanofi’s branded insulin glargine drug Lantus by improperly listing several drugs in the Orange Book.
In its amicus brief filed in Mylan Pharmaceuticals Inc., et al. v. Sanofi-Aventis U.S. LLC, et al., the FTC explains that improper Orange Book listings, such as those alleged in Mylan’s case, can cause significant harm to competition, including delaying consumer access to a lower-priced competing drug that would save patients money while also potentially offering better access and higher quality medications.
As detailed in the FTC’s amicus brief, when a brand pharmaceutical company lists a patent in the Orange Book it may lead to a statutory stay that blocks the introduction of competing drug products for up to 30 months, including lower-cost generic alternatives. When this stay is triggered by a patent that is improperly filed and does not meet the statutory listing criteria, the stay may improperly delay consumer access to a competing product that might reduce prices, improve quality and access, or both. Given the high cost of many drugs, even a short delay in competition can have enormous consequences for consumers in accessing cost-effective medications, the FTC stated in the brief.
In September, the FTC issued a policy statement which warned that the agency would be scrutinizing the improper submission of patents for listing in the Orange Book. The Commission’s statement warned that improper listings in the Orange Book may harm competition from cheaper generic alternatives and keep brand prices artificially high. In November, the FTC sent letters to 10 drug manufacturers notifying them of more than 100 improperly listed Orange Book patents.
The FTC’s amicus brief was filed in the U.S. District Court for the Western District of Pennsylvania. The Commission vote approving the filing of the amicus brief was 3-0. The Commission takes no position on Mylan’s allegations.
The Federal Trade Commission works to promote competition, and protect and educate consumers. As part of the FTC’s policy work, the Commission submits amicus briefs in cases involving areas of law relevant to its competition and consumer protection missions to provide information that can help courts to make their decisions in ways that protect consumers or promote competition. You can learn more about how competition benefits consumers or file an antitrust complaint. For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.
,
Office of Public Affairs,
415-848-5121
